Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bobby Thomas

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Antioxidants & Redox Signaling|July 24, 2009
Parkinson's disease: from molecular pathways in disease to therapeutic approachesBobby Thomas
Human Molecular Genetics|October 4, 2007
Parkinson's diseaseBobby Thomas, M Flint Beal
Neural Regeneration Research|January 27, 2017
The status of Nrf2-based therapeutics: current perspectives and future prospectsIrina G Gazaryan, Bobby Thomas
Movement Disorders : Official Journal of the Movement Disorder Society|February 27, 2010
Mitochondrial therapies for Parkinson's diseaseBobby Thomas, M Flint Beal
F1000 Medicine Reports|June 10, 2011
Molecular insights into Parkinson's diseaseBobby Thomas, M Flint Beal
Neurochemistry International|March 19, 2018
Current perspective of mitochondrial biology in Parkinson's diseaseNavneet Ammal Kaidery, Bobby Thomas
Journal of Pineal Research|December 17, 2003
Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatumBobby Thomas, Kochupurackal P Mohanakumar
Molecular and Cellular Neurosciences|October 24, 2019
Crosstalk between Nrf2 signaling and mitochondrial function in Parkinson's diseaseNavneet Ammal Kaidery, Manuj Ahuja, Bobby Thomas
Trends in Neurosciences|October 16, 2010
Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implicationsRebecca Banerjee, M Flint Beal, Bobby Thomas
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 14, 2013
Epigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalitiesNavneet Ammal Kaidery, Shaista Tarannum, Bobby Thomas
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Antioxidants & Redox Signaling|July 24, 2009
Parkinson's disease: from molecular pathways in disease to therapeutic approachesBobby Thomas
Human Molecular Genetics|October 4, 2007
Parkinson's diseaseBobby Thomas, M Flint Beal
Neural Regeneration Research|January 27, 2017
The status of Nrf2-based therapeutics: current perspectives and future prospectsIrina G Gazaryan, Bobby Thomas
Movement Disorders : Official Journal of the Movement Disorder Society|February 27, 2010
Mitochondrial therapies for Parkinson's diseaseBobby Thomas, M Flint Beal
F1000 Medicine Reports|June 10, 2011
Molecular insights into Parkinson's diseaseBobby Thomas, M Flint Beal
Neurochemistry International|March 19, 2018
Current perspective of mitochondrial biology in Parkinson's diseaseNavneet Ammal Kaidery, Bobby Thomas
Journal of Pineal Research|December 17, 2003
Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatumBobby Thomas, Kochupurackal P Mohanakumar
Molecular and Cellular Neurosciences|October 24, 2019
Crosstalk between Nrf2 signaling and mitochondrial function in Parkinson's diseaseNavneet Ammal Kaidery, Manuj Ahuja, Bobby Thomas
Trends in Neurosciences|October 16, 2010
Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implicationsRebecca Banerjee, M Flint Beal, Bobby Thomas
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 14, 2013
Epigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalitiesNavneet Ammal Kaidery, Shaista Tarannum, Bobby Thomas
Pageof 7